Key result
Pretreatment with aliskiren ameliorated ischemia/reperfusion-induced renal injury in rats by decreasing nitric oxide and angiotensin II levels and down-regulating IL-1β, iNOS, and NFkB expression.
Why the study?
Does aliskiren pretreatment ameliorate renal ischemia/reperfusion injury in a rat model?
Population
Rat renal ischemia-reperfusion model
Comparison
Aliskiren administered orally by gavage 24 and 1… vs Sham control group, sham control with aliskiren…
Design
Preclinical, Rats were randomly divided into five groups
Follow-up
24 hours (reperfusion period)
Authors
Loading...
Caution against clinical use in renal I/R; leaves open translation from this rat model to human trials.
RCT
randomly divided
Does aliskiren pretreatment ameliorate renal ischemia/reperfusion injury in a rat model?
In a rat model, aliskiren pretreatment protected against renal ischemia/reperfusion injury by modulating inflammatory and oxidative stress pathways.
Ziypak et al. (2014) conducted an RCT in renal ischemia/reperfusion injury. Aliskiren vs. sham control and ischemia/reperfusion without pretreatment was evaluated on malondialdehyde (MDA) level, superoxide dismutase (SOD), glutathione (GSH) activity, histological evaluation, serum creatinine, blood urea nitrogen, renin, and angiotensin II. Pretreatment with aliskiren ameliorated ischemia/reperfusion-induced renal injury in rats by decreasing nitric oxide and angiotensin II levels and down-regulating IL-1β, iNOS, and NFkB expression.
Synapse has enriched one closely related paper. Consider it for comparative context: